A natural experiment in Kenya reveals durable immunosuppressive effects of early childhood malaria: a longitudinal cohort study

Mercy S. Safari[1,2,6], Timothy O. Makori[1,2], Elijah T. Gicheru[1,2], Maureen W. Mburu[1,2], Omar Nyawa[1,2], Faiz Shee[6], James Nyagwange[1], Eunice W. Kagucia[1], Francis Ndungu[1,3], Timothy Chege[2,5], James O. Tuju[1,7#], Charles J. Sande[1,2,3,4*#]

1. Bioscience Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
2. Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
3. Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK
4. Kenya Medical Research Institute, Centre for Geographic Medicine Research, Coast, Kilifi, Kenya
5. Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 100322 USA
6. Pwani University, Kilifi, Kenya,
7. Imperial College London

* Correspondence to:
Charles J. Sande, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya P.O. Box 230 - 80108 (csande@kemri-wellcome.org)

# Contributed equally

Keywords: malaria, antibody immunosuppression, microarray

Abstract

Background:

Chronic malaria exposure has been proposed to modulate immune function, but its long-term effects on antibody-mediated responses to unrelated pathogens remain poorly defined. Whether these effects persist beyond periods of active infection, and how early-life exposure shapes humoral immunity over time, is not well understood.

Methods:

We leveraged a natural experiment in coastal Kenya - where two regions (Junju and Ngerenya) diverged sharply in malaria transmission from around 2004 - to evaluate the long-term immunological consequences of malaria exposure in childhood. Using a protein microarray platform, we measured IgG responses to vaccine and pathogen antigens in 123 children sampled longitudinally over a 15-year period. Active weekly malaria surveillance enabled precise reconstruction of individual exposure histories.

Results:

IgG responses to *Plasmodium falciparum* apical membrane antigen 1 (AMA1) tracked closely with clinical malaria episodes, confirming the ability of the microarray platform to detect biologically meaningful variation in antigen-specific immunity. Despite comparable vaccination histories, children from the high malaria transmission setting (Junju) exhibited persistently lower measles-specific IgG levels than children from the low-transmission setting (Ngerenya), a pattern validated by ELISA. At 10 years of age, Junju children showed significantly reduced antibody levels to a wide range of unrelated pathogens, including *Bordetella pertussis*, CMV, rubella, and measles. Within the Ngerenya cohort, children with documented early-life malaria had broadly lower IgG responses at age 10 compared to malaria-naïve peers, despite identical geography, vaccines, and follow-up duration.

Conclusions:

These findings suggest that malaria exposure during early childhood is linked with durable suppression of antibody responses to unrelated pathogens and vaccines. This effect persists long after infection and may partially explain the overall diminished long-term vaccine effectiveness in malaria-endemic settings.

Introduction

Malaria remains a major cause of childhood morbidity and mortality in sub-Saharan Africa. In 2023, Africa accounted for 95% of global malaria deaths, with over three-quarters occurring in children under five years old[1]. Alongside malaria, children in these settings face high exposure to a wide array of pathogens - including respiratory, enteric, and helminth infections [2], making immune competence critical for survival and long-term health. Despite widespread vaccination efforts, several studies report reduced vaccine efficacy in malaria-endemic regions compared to malaria-naïve populations [3–5]. Although multiple factors may contribute[6], growing evidence suggests that malaria itself can impair host immunity[5,7,8]. Repeated P. falciparum infection has been associated with immunomodulatory changes, including expansion of regulatory T cells [9,10], regulatory B cells[11], and atypical memory B cells with limited effector function[12,13]. These alterations promote host tolerance for persistent parasitaemia, resulting from recurrent exposure in endemic settings, but they also suppress effector immune responses[14], potentially to unrelated antigens, including vaccines. While malaria-induced immunosuppression has been described in both experimental and observational studies[7,8,15,16], its duration and broader impact on the developing immune system remain poorly understood. Most prior work has focused on short-term or antigen-specific outcomes, leaving open the question of whether early-life malaria exposure durably attenuates antibody responses over the long term. Conflicting findings across settings highlight the need for context-specific, and longitudinal data studies[16,17].

Here, we address this gap using two longitudinal cohorts from coastal Kenya with contrasting malaria transmission histories. One region (Junju) has experienced a sustained malaria burden, while the other (Ngerenya) underwent a rapid decline in transmission after 2004[18]. Intensive weekly malaria surveillance was conducted over more than a decade, enabling precise classification of individual exposure histories. We combined these data with serial serological measurements using a high-throughput in-house protein microarray. This design enabled us to investigate whether clinical malaria in early life leaves a lasting immunological imprint that compromises antibody responses to common childhood pathogens and vaccines. Our findings reveal a durable

89 suppression of humoral immunity linked to malaria exposure in early childhood, with
90 implications for vaccine effectiveness, serosurveillance interpretation, and immune
91 recovery in endemic regions.

92 **Materials and Methods**

93 **Study setting and cohort design -** This study was conducted in Kilifi County, a rural
94 region on the northern coast of Kenya, within the catchment area of the Kilifi Health and
95 Demographic Surveillance System (KHDSS), a long-term population-based platform
96 maintained by the KEMRI-Wellcome Trust Research Programme[19]. Serum samples were
97 obtained retrospectively from two well-characterised paediatric cohorts - Ngerenya and
98 Junju - enrolled between 1998 and 2017 as part of annual malaria cross-sectional
99 surveys[20]. Ngerenya and Junju were selected for their contrasting malaria transmission
100 intensities; Ngerenya experienced a sharp decline in malaria transmission beginning in
101 the early 2000s[18], whereas Junju maintained moderate malaria endemicity throughout
102 the study period, with *P.falciparum* prevalence approximating 30% during the rainy
103 seasons[21]. All children were visited weekly at home for the detection of febrile episodes,
104 and any child with an axillary temperature ≥37.5°C was tested for P. falciparum
105 parasitaemia using a rapid diagnostic test, with confirmation by microscopic
106 examination of Giemsa-stained thick and thin blood smears. A clinical malaria episode
107 was defined as fever in the presence of ≥2,500 parasites/µL. In addition to active malaria
108 surveillance, serum samples were collected annually from each child and for future
109 serological analysis. The vaccination status of each child for routine childhood vaccines
110 was assessed using digitised immunisation records stored at the KEMRI-Wellcome Trust
111 Research Programme.

112 **Protein microarray antibody profiling -** Antibody responses were measured using an in-
113 house protein microarray platform. Recombinant and whole-virus lysate antigens
114 (Supplementary table 1) were reconstituted in a glycerol-based buffer containing 1%
115 Triton X-100 and printed in quadruplicate onto epoxy-coated glass slides using a non-
116 contact microarrayer (Marathon Argus, Arrayjet, Scotland). Slides were fitted into
117 hybridisation cassettes, washed with PBST (0.05% Tween-20 in PBS), and blocked for 1
118 hour at 37°C using PBST containing 5% BSA. Serum samples were diluted 1:30 in PBST

with 5% BSA and incubated on the slides for 3 hours at room temperature. Slides were washed and probed with secondary antibodies: goat anti-human IgG conjugated to Alexa Fluor 647 (SouthernBiotech, cat. no. 2040-03) and goat anti-human IgA conjugated to Alexa Fluor 555 (SouthernBiotech, cat. no. 2050-32), each incubated for 1.5 hours at 25°C. Slides were rinsed, disassembled, and scanned using a GenePix 4300A scanner (635 nm at PMT 600, 532 nm at PMT 700). Mean fluorescence intensities (MFIs) were extracted from duplicate mini-arrays per slide and averaged across four replicate spots per antigen. Data processing and quality control of microarray data were performed in R (version 4.4.2).

Enzyme-linked immunosorbent assay (ELISA) - Measles-specific IgG was quantified using a conventional direct ELISA. Plates were coated overnight at 4°C with 2.30 µg/mL measles antigen diluted in PBS. After blocking with 5% skimmed milk for 1 hour at 37°C, serum samples (1:100 dilution) were added and incubated for 1.5 hours at 37°C. Plates were washed with PBST and incubated with HRP-conjugated secondary antibody (1:100 dilution) for 1 hour. Following additional washes, 100 µL of OPD substrate solution (30 mg OPD in 30 mL PBS with 30 µL H_2O_2) was added and incubated in the dark for 10 minutes. Reactions were stopped with 50 µL of 2.5 M sulfuric acid, and absorbance was measured at 490 nm.

Statistical analysis - All statistical analyses were performed using R (version 4.4.2). Antibody responses between cohorts were compared using the Wilcoxon rank-sum test. P-values <0.05 were considered statistically significant. Data were anonymised and delinked from all personally identifiable information.

Ethics statement - The study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical Research Institute. All procedures were conducted in accordance with the principles of Good Clinical Laboratory Practice (GCLP).

Results

A natural experiment in coastal Kenya reveals sharply divergent malaria exposure trajectories in early childhood - Between 1998 and 2017, two rural communities in coastal Kenya - Junju and Ngerenya - underwent markedly different transitions in malaria

transmission. Both regions experienced a high malaria burden in the 1990s and early 2000s. However, beginning in 2004, transmission in Ngerenya declined sharply and remained near zero for more than a decade, while Junju continued to experience sustained endemicity well into the mid-2010s. To quantify the scale and timing of this transition, we analysed surveillance data collected from August 1998 to April 2017. A total of 1,243 children were followed in Ngerenya and 659 in Junju. In Ngerenya, the proportion of febrile surveillance visits with confirmed P. falciparum parasitaemia declined from 22.4% before 2004 (1,378 of 6,148 visits) to just 1.1% after 2004 (48 of 4,389 visits). In contrast, Junju children continued to experience high rates of febrile malaria, with 17% of visits testing positive between 2007 and 2017 (869 of 5,130 visits) - **Fig. 1**.

To assess whether the protein microarray platform accurately captured longitudinal P. falciparum-specific immune responses, we examined IgG levels against the plasmodium apical membrane antigen 1 (AMA1) in individual children with known malaria exposure histories. Among children with multiple confirmed episodes of febrile malaria detected via weekly active surveillance, AMA1-specific IgG levels increased sharply over time, tracking closely with the timing of clinical infections (example shown in **Fig. 2a**), while children from Ngerenya who remained malaria-free throughout follow-up exhibited consistently low IgG levels against AMA1 over more than a decade of surveillance (example shown in **Fig. 2b**). These patterns mirrored expected immunological trajectories of repeated exposure versus non-exposure, confirming that the microarray platform is capable of detecting meaningful variation in P. falciparum-specific humoral responses. We then extended this analysis to assess longitudinal IgG responses to AMA1 in a subset of 123 children drawn from the two surveillance cohorts. These children contributed a total of 1,194 serum samples, with a mean of 10 samples per child, collected between 2002 and 2017 (**Supplementary Fig. 1**). This subset was selected on the basis of the relative completeness of their longitudinal follow-up serum sampling and included 58 children from Junju (505 samples) and 65 from Ngerenya (689 samples). AMA1-specific IgG levels diverged sharply between cohorts early in life and remained distinct throughout follow-up. In Ngerenya, levels declined rapidly after 2003, stabilising

179 at lower levels by mid-childhood. In contrast, Junju children maintained elevated levels
180 across all time points (**Fig. 2c**).
181
182 **Malaria-exposed children exhibit lower antibody levels to non-malarial antigens -** To
183 examine the impact of differential malaria endemicity on the antibody response to non-
184 malarial antigens, we first compared IgG responses to the measles virus among Junju and
185 Ngerenya children. We started by validating the ability of the in-house protein microarray
186 platform to detect biologically meaningful measles-specific IgG responses by examining
187 longitudinal measles levels in individual children with known vaccination histories.
188 Among children with a documented history of receiving all three recommended doses of
189 measles vaccine, we observed a sharp rise in IgG levels following immunisation, followed
190 by sustained levels into later childhood (example shown in **Fig. 3a**). In contrast,
191 unvaccinated children exhibited consistently low IgG trajectories across all time points
192 (example shown in **Fig. 3b**). These patterns were reproducible across the cohort and
193 recapitulated expected vaccine-induced versus naïve antibody dynamics, supporting the
194 use of this platform for population-level serological inference. Using this platform, we
195 then compared IgG responses to measles virus among children from Junju and Ngerenya.
196 This analysis was restricted only to children with a documented record of measles
197 vaccination. Despite matched vaccination histories, children from Junju - where malaria
198 transmission remained high - consistently exhibited lower measles-specific IgG titres
199 than children from Ngerenya, where malaria transmission had declined. This difference
200 was evident from the earliest timepoints and persisted throughout childhood. Annual
201 antibody measurements showed that mean measles-specific IgG levels were higher in
202 Ngerenya than in Junju in every sampling year (**Fig. 3c**). To validate these findings, we
203 measured measles-specific IgG levels by ELISA in a subset of 3-year-old children who
204 had completed measles vaccination at least one year prior. In this assay, Junju children
205 again displayed significantly lower IgG levels than their Ngerenya counterparts (**Fig. 3d**).
206
207 **Early-life malaria exposure is associated with long-term suppression of antibody**
208 **responses** To assess whether the attenuation of antibody responses extended beyond
209 measles, we compared IgG levels to a broader panel of antigens at 10 years of age. This
210 analysis included vaccine-preventable pathogens (*Bordetella pertussis*, H1N1 influenza

211 virus, rubella virus, and measles virus) and common childhood infections
212 (cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1 (HSV-1),
213 coxsackievirus B1). Children from Junju exhibited significantly lower IgG levels for most
214 antigens compared to their Ngerenya counterparts (**Fig. 4**). This pattern was observed for
215 both viral and bacterial pathogens and was particularly marked for coxsackievirus, EBV,
216 HSV-1, and measles. Antibody levels against P. falciparum AMA1 remained elevated in
217 Junju. Antibody levels to the 2009 pandemic strain of H1N1 were the least differentiated
218 between cohorts, although Ngerenya children still exhibited significantly higher levels
219 than Junju participants (**Fig. 4**).
220
221 To determine whether the attenuation of antibody responses could still be attributed to
222 early-life malaria exposure independent of geographic or environmental differences, we
223 conducted a stratified analysis within the Ngerenya cohort, which experienced a sharp
224 decline in malaria transmission beginning in 2004. Due to stochastic differences in
225 malaria infection around the time of this inflection, children in Ngerenya had different
226 malaria exposure histories despite living in the same area. At the 10-year-of-age time
227 point, sera were available for 62 out of the 65 children that were originally selected in the
228 Ngerenya cohort subset for serological analysis. Of these, 20 experienced one or more
229 episodes of febrile malaria during early childhood prior to the decline in malaria
230 transmission, while 42 remained entirely malaria-free throughout follow-up (**Fig. 5a**). At
231 10 years of age, Ngerenya children who had experienced early-life malaria exhibited
232 significantly lower IgG levels to a wide range of antigens compared to their malaria-naïve
233 peers (**Fig. 5b**). These included responses to Coxsackievirus B1, CMV, H1N1 influenza,
234 HSV-1 and rubella. Differences in antibody level to *B. pertussis* and EBV did not reach
235 statistical significance.
236
237 **Discussion**
238 This study demonstrates that early-life exposure to malaria is associated with broad and
239 durable impairments in antibody-mediated immunity to unrelated pathogens and
240 vaccines. By leveraging a natural experiment in coastal Kenya - where malaria
241 transmission diverged sharply between adjacent communities during the early 2000s -
242 we were able to disentangle the immunological effects of malaria exposure from

243 confounding geographic and temporal factors. Our findings reveal that children exposed
244 to malaria in early childhood not only generate lower antibody titres to non-malarial
245 antigens but maintain these attenuated responses well into adolescence, long after
246 malaria transmission has ceased. The attenuating effect of malaria on antibody
247 responses has long been suspected [15] but difficult to quantify. Prior studies have shown
248 reduced vaccine efficacy in malaria-endemic settings [3,16], and experimental models have
249 implicated regulatory T cells, atypical memory B cells, and B cell exhaustion as potential
250 mediators of malaria-induced immune suppression[9,12,13,22]. However, most human
251 studies to date have focused on short-term immune responses or outcomes in the
252 setting of concurrent parasitaemia. Our data extend this work by demonstrating that
253 transient exposure to malaria in early childhood is sufficient to imprint long-lasting
254 changes on the humoral immune repertoire.
255
256 The strength of this study lies in its integration of long-term active malaria surveillance
257 with serial antibody profiling. Children were visited weekly for febrile illness surveillance,
258 allowing for precise documentation of clinical malaria episodes. In parallel, our use of a
259 validated protein microarray platform enabled us to track IgG responses to a wide panel
260 of pathogen and vaccine antigens at multiple timepoints. We first confirmed that the
261 microarray platform captured biologically relevant responses by comparing antibody
262 trajectories in individual children with known measles vaccination and malaria exposure
263 histories. The platform reliably detected both vaccine-induced and infection-associated
264 rises in IgG, providing confidence in the longitudinal patterns observed. We found that
265 children from Junju, a region of persistent transmission, had significantly lower antibody
266 levels to multiple pathogens compared to children from Ngerenya, where malaria
267 transmission declined in the mid-2000s. These differences were most pronounced for
268 antigens such as measles virus, *Bordetella pertussis*, CMV, rubella virus, and HSV-1.
269 Importantly, all children had comparable vaccination histories and were followed
270 through the same longitudinal infrastructure, minimising the likelihood of differential
271 healthcare access or vaccine uptake.
272
273 To test whether early-life malaria exposure specifically contributed to long-term immune
274 suppression, we examined antibody responses within the Ngerenya cohort. Because the

transmission decline occurred rapidly, children born just before and after the inflection point experienced markedly different levels of malaria exposure while living in the same geographic area. Among children followed longitudinally, those with even limited early-life exposure to malaria had significantly lower antibody titres at 10 years of age than their malaria-naïve peers. This within-cohort contrast strongly implicates early-life infection as the critical window for immune programming. Taken together, these findings support a model in which malaria exposure during critical developmental windows modulates long-term maintenance of immune memory. This may occur through direct effects on B cell maturation, altered antigen presentation[23], or long-lived changes in lymphoid microenvironments[24–26]. While the mechanistic basis of this phenomenon remains to be fully explained, the consistency of the attenuation on multiple antigens and timepoints suggests a generalizable effect rather than antigen-specific phenomenon.

This work has important implications for vaccine policy and infection risk in malaria-endemic regions. Reduced antibody titres to vaccine-preventable diseases may translate into diminished long-term protection, even when vaccine coverage is high. Our findings raise the possibility that children in high-transmission settings may require different immunisation strategies, such as delayed dosing and boosting, to improve vaccine-induced immunity. Moreover, as malaria control efforts continue to shift disease epidemiology, these data highlight the value of longitudinal serological surveillance for understanding the broader immunological legacy of malaria exposure. Our study has several limitations. Although the microarray platform was validated internally and against ELISA, quantitative comparisons across platforms are inherently constrained. Additionally, while the sample size for antibody profiling was modest, the inclusion of dense longitudinal sampling and detailed clinical surveillance adds depth to the dataset. Finally, we cannot fully exclude the influence of other infections or environmental exposures that may have differed subtly between subgroups, although the within-Ngerenya analysis provides strong evidence for malaria as a primary driver of long-term immune attenuation.

In summary, our findings reveal that early-life malaria exposure is associated with long-term suppression of antibody responses to unrelated pathogens and vaccines. This

307 effect is detectable many years after infection, and appears to persist even in the
308 absence of ongoing transmission. As global malaria control efforts continue,
309 understanding the immunological legacy of childhood malaria may be critical for
310 improving vaccination strategies and mitigating susceptibility to other infections.

Figures



Figure 1


a.
Junju participant
AMA1 antibody response
Mean fluorescent intensity (MFI)
50000
40000
30000
20000
10000
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
year
b.
Ngerenya participant
AMA1 antibody response
50000
40000
30000
20000
10000
0
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
year
c.
AMA1 antibody response
Mean fluorescent intensity (MFI)
30000
20000
10000
0
2002
2003
2004
2005
2007
2008
2009
2010
2011
2012
2014
2015
2016
2017
year
cohort
ngerenya
junju

Figure 2

317

318



319

320 Figure 3


B. pertussis
Coxsackievirus B1
Cytomegalovirus
Epstein–Barr Virus
H1N1 Influenza (2009pdm strain)
Herpes Simplex Virus 1
Measles
Rubella
Mean fluorescent intensity (MFI)
32768
2048
128
8
junju
ngerenya
cohort
junju
ngerenya

Figure 4


a.
Prior malaria episodes: no
Prior malaria episodes: yes
Ngerenya cohort participants
Date of malaria surveillance visit
Febrile malaria
No
Yes
b.
B. pertussis
Coxsackievirus B1
Cytomegalovirus
Epstein–Barr Virus
H1N1 Influenza (2009pdm strain)
Herpes Simplex Virus 1
Measles
Rubella
Mean fluorescent intensity (MFI)
60000
40000
20000
ns
*
**
no
yes
Prior malaria exposure

326 Figure 5

Figure captions

Figure 1

Divergent malaria exposure histories in coastal Kenya - Monthly malaria case counts from active surveillance in two adjacent regions of Kilifi County, Kenya, between 1998 and 2017. Junju (red) maintained sustained malaria transmission throughout the study period, while Ngerenya (blue) experienced a rapid collapse in transmission beginning in 2004. Points represent total cases per month; lines show LOESS-smoothed trends.

Figure 2

AMA1-specific IgG trajectories mirror individual and regional malaria exposure - (A–B) Longitudinal AMA1 IgG levels in individual children measured by protein microarray. Vertical red lines denote confirmed febrile malaria episodes. Panel A shows a Junju child with multiple documented infections; Panel B shows a Ngerenya child who remained malaria-free throughout follow-up. Each blue spot is a single antibody measurement. Each time point was measured in quadruplicate **(C)** Mean AMA1-specific IgG levels with 95% confidence intervals for all children in the microarray subset plotted by year of sampling. Junju children showed persistently elevated antibodies, while AMA1 antibody levels in Ngerenya declined sharply after 2004.

Figure 3

Malaria exposure is associated with reduced measles-specific antibody levels. Example plots of temporal changes in measles-specific antibody in vaccinated and unvaccinated children are shown **(A)** Longitudinal IgG levels in an individual child measured by microarray. The dashed vertical red line indicates the timing of the last dose of the routine measles vaccine. **(B)** Shows a similar temporal trend for a child with no history of measles vaccination. **(C)** Longitudinal IgG responses to measles virus by cohort, measured by protein microarray in vaccinated children. Junju children exhibited consistently lower levels of measles-specific antibody than Ngerenya counterparts. The circles indicate means, and the whiskers denote 95% confidence intervals. **(D)** Measles-specific IgG levels in 3-year-old children from Junju and Ngerenya, measured by ELISA in

358 children with a documented history of measles vaccination. Each dot represents an
359 individual participant.
360
361 **Figure 4**
362 **Broad suppression of antibody responses to diverse pathogens in malaria-exposed**
363 **children - cross**-sectional IgG titres at 10 years of age for a panel of pathogen and
364 vaccine antigens, measured by protein microarray. Each dot represents an individual
365 child; boxes indicate interquartile ranges, with the midline denoting the median. Junju
366 children show significantly lower antibody levels across most antigens compared to
367 Ngerenya children, including *Bordetella pertussis*, H1N1 influenza virus, rubella virus,
368 measles virus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus 1
369 (HSV-1), and coxsackievirus B1.
370
371
372 **Figure 5**
373 **Early-life malaria exposure predicts long-term suppression of antibody responses**
374 **within the same geographic region - (A)** Active malaria surveillance records for children
375 in the Ngerenya cohort. Each row represents an individual child, and each column
376 represents a surveillance timepoint. Dark red boxes indicate one or more confirmed
377 febrile malaria episodes; light grey boxes indicate surveillance visits without malaria
378 detection. Children are grouped by early-life exposure status (top: malaria-naïve;
379 bottom: previously exposed). **(B)** IgG levels at 10 years of age among Ngerenya children,
380 stratified by early-life malaria exposure. Children with ≥1 confirmed febrile malaria
381 episode during early childhood (n = 20) show significantly lower titres to multiple
382 unrelated pathogens compared to malaria-naïve peers (n = 42). All children lived in the
383 same geographic area and received identical vaccines and follow-up. The black dots are
384 means and error bars are 95% confidence intervals.
385
386 **Supplementary Figure 1**
387 A summary of the sampling frame for the study cohorts (Junju and Ngerenya). Each
388 vertical line represents the longitudinal time series for a single individual, and each dot
389 represents a timepoint where a serum sample was collected.

Supplementary Table 1

Summary of pathogens, strains or subtypes, and corresponding antigens included in the immunoassay panel.

Data and Code Availability

The datasets and R scripts used for the analysis in this study are available from the corresponding author upon reasonable request. Due to local laws and regulations, individual-level data from the Kilifi Health and Demographic Surveillance System (KHDSS), cannot be made publicly available. All data processing and visualisation were performed using open-source R packages; package versions and analysis pipelines are available upon request.

Funding statement

This study was supported by fellowship funding to C.J.S. from the Wellcome Trust (WT105882MA). The funder played no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript. M.S.S was funded in whole by Science for Africa Foundation to the Developing Excellence in Leadership, Training, and Science in Africa (DELTAS Africa) program [DEL-22-012] with support from Wellcome Trust and the UK Foreign, Commonwealth & Development Office and is part of the EDCPT2 programme supported by the European Union. For purposes of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

References

1 World Health Organization. World malaria report 2024. Geneva, 2024 https://www.who.int/publications/i/item/9789240086173.

2 Reiner RC, LBD Triple Burden Collaborators, Welgan CA, *et al.* The overlapping burden of the three leading causes of disability and death in sub-Saharan African children. *Nat Commun* 2022; **13**: 7457.

3 Bejon P, Mwacharo J, Kai O, *et al.* The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. *J Immunol* 2007; **179**: 4193–201.

4 RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, *et al.* A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. *N Engl J Med* 2012; **367**: 2284–95.

5 Cunnington AJ, Riley EM. Suppression of vaccine responses by malaria: insignificant or overlooked? *Expert Rev Vaccines* 2010; **9**: 409–29.

6 P Z, N C. Factors That Influence the Immune Response to Vaccination. *PubMed* 2019. https://pubmed.ncbi.nlm.nih.gov/30867162/ (accessed April 25, 2025).

7 Bediako Y, Adams R, Reid AJ, *et al.* Repeated clinical malaria episodes are associated with modification of the immune system in children. *BMC Med* 2019; **17**: 60.

8 Calle CL, Mordmüller B, Singh A. Immunosuppression in Malaria: Do Plasmodium falciparum Parasites Hijack the Host? *Pathogens* 2021; **10**: 1277.

9 Kurup SP, Obeng-Adjei N, Anthony SM, *et al.* Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. *Nat Med* 2017; **23**: 1220–5.

10 Walther M, Tongren JE, Andrews L, *et al.* Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. *Immunity* 2005; **23**: 287–96.

11 Han X, Yang J, Zhang Y, *et al.* Potential Role for Regulatory B Cells as a Major Source of Interleukin-10 in Spleen from Plasmodium chabaudi-Infected Mice. *Infect Immun* 2018; **86**: e00016-18.

12 Illingworth J, Butler NS, Roetynck S, *et al.* Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. *J Immunol* 2013; **190**: 1038–47.

13 Weiss GE, Crompton PD, Li S, *et al.* Atypical Memory B Cells Are Greatly Expanded in Individuals Living in a Malaria-Endemic Area. *The Journal of Immunology* 2009; **183**: 2176–82.

14 Portugal S, Moebius J, Skinner J, *et al.* Exposure-dependent control of malaria-induced inflammation in children. *PLoS Pathog* 2014; **10**: e1004079.

15 Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. Immunosuppression in children with malaria. *Lancet* 1972; **1**: 169–72.

16 Zirimenya L, Natukunda A, Nassuuna J, *et al*. The Effect of Malaria on Responses to Unrelated Vaccines in Animals and Humans: A Systematic Review and Meta-Analysis. *Parasite Immunology* 2024; **46**: e13067.

17 Crawley J, Sismanidis C, Goodman T, Milligan P. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. *The Lancet* 2012; **380**: 1001–10.

18 O'Meara WP, Mwangi TW, Williams TN, McKenzie FE, Snow RW, Marsh K. Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. *Am J Trop Med Hyg* 2008; **79**: 185–91.

19 Scott JAG, Bauni E, Moisi JC, *et al*. Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). *Int J Epidemiol* 2012; **41**: 650–7.

20 Mwangi TW, Ross A, Snow RW, Marsh K. Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. *J Infect Dis* 2005; **191**: 1932–9.

21 Bejon P, Williams TN, Liljander A, *et al*. Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. *PLoS Med* 2010; **7**: e1000304.

22 Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory B cells in human chronic infectious diseases: An interim report. *Cell Immunol* 2017; **321**: 18–25.

23 Yap XZ, Lundie RJ, Beeson JG, O'Keeffe M. Dendritic Cell Responses and Function in Malaria. *Front Immunol* 2019; **10**: 357.

24 Cadman ET, Abdallah AY, Voisine C, *et al*. Alterations of splenic architecture in malaria are induced independently of Toll-like receptors 2, 4, and 9 or MyD88 and may affect antibody affinity. *Infect Immun* 2008; **76**: 3924–31.

25 Obeng-Adjei N, Portugal S, Holla P, *et al*. Malaria-induced interferon-γ drives the expansion of Tbethi atypical memory B cells. *PLoS Pathog* 2017; **13**: e1006576.

26 Weiss GE, Traore B, Kayentao K, *et al*. The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. *PLoS Pathog* 2010; **6**: e1000912.

Supplementary Materials



Supplementary figure 1

488

489

490

Pathogen	Strain/subtype	Antigen
Measles virus	Edmonston	Whole virus antigen
Coxsackie B virus	B1	VP1
Cytomegalovirus	TB40E	PP150
Epstein-Barr virus	Type 1	Nuclear antigen 1
Herpes simplex virus	Type 1	Extract
H1N1 Influenza A	A/California/07/2009	Haemagluttinin
Plasmodium falciparum	3D7	AMA-1
Rubella virus	HPV-77	Whole virus antigen

491

492

493 Supplementary table 1